FREQUENCY THERAPEUTICS, INC. (FREQ): Price and Financial Metrics


FREQUENCY THERAPEUTICS, INC. (FREQ): $4.02

-0.04 (-0.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FREQ to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FREQ Stock Price Chart Interactive Chart >

Price chart for FREQ

FREQ Price/Volume Stats

Current price $4.02 52-week high $5.66
Prev. close $4.06 52-week low $1.00
Day low $4.02 Volume 2,549
Day high $4.02 Avg. volume 342,075
50-day MA $3.17 Dividend yield N/A
200-day MA $2.11 Market Cap 141.75M

FREQUENCY THERAPEUTICS, INC. (FREQ) Company Bio


Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. T


FREQ Latest News Stream


Event/Time News Detail
Loading, please wait...

FREQ Latest Social Stream


Loading social stream, please wait...

View Full FREQ Social Stream

Latest FREQ News From Around the Web

Below are the latest news stories about FREQUENCY THERAPEUTICS INC that investors may wish to consider to help them evaluate FREQ as an investment opportunity.

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

LEXINGTON, Mass., December 19, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clinical development and translation eff

Yahoo | December 19, 2022

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

LEXINGTON, Mass., December 15, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Company’s second hearing restoration candidate for sensorineural hearing loss (SNHL).

Yahoo | December 15, 2022

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

LEXINGTON, Mass., November 17, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical r

Yahoo | November 17, 2022

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

LEXINGTON, Mass., November 08, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.

Yahoo | November 8, 2022

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

LEXINGTON, Mass., October 12, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of s

Yahoo | October 12, 2022

Read More 'FREQ' Stories Here

FREQ Price Returns

1-mo 1.77%
3-mo 67.50%
6-mo 80.27%
1-year -28.47%
3-year -84.91%
5-year N/A
YTD 4.42%
2022 -24.95%
2021 -85.45%
2020 101.14%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5996 seconds.